FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

FDA approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors.
Source: FDA Press Releases